ADHD

12
Pipeline Programs
8
Companies
13
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
1
5
4
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
MODAFINILApproved
modafinil
Unknown Company
Sympathomimetic-like Agent [EPC]oral2012
U
PROVIGILApproved
modafinil
Unknown Company
Sympathomimetic-like Agent [EPC]oral1998

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
1
1
Mixed amphetamine saltsPhase 41 trial
SPD544Phase 11 trial
Active Trials
NCT01183234Completed28Est. Oct 2010
NCT00506727Completed215Est. Jul 2004
Pfizer
PfizerNEW YORK, NY
1 program
1
Very Low Dose Quillivant XRPhase 41 trial
Active Trials
NCT02255565Completed36Est. Oct 2016
Zevra Therapeutics
Zevra TherapeuticsDenmark - Frederiksberg
2 programs
2
KP415 oral capsulePhase 31 trial
KP415 oral capsulePhase 31 trial
Active Trials
NCT03292952Completed155Est. May 2018
NCT03460652Completed282Est. Jul 2019
Novartis
NovartisBASEL, Switzerland
1 program
1
Focalin XRPhase 32 trials
Active Trials
NCT00141063Completed90Est. Aug 2005
NCT00141050Completed90Est. Jul 2005
Teva
TevaIsrael - Petach Tikva
1 program
1
ModafinilPhase 31 trial
Active Trials
NCT00228540CompletedEst. Sep 2006
Axsome Therapeutics
Axsome TherapeuticsNY - New York
1 program
1
Solriamfetol 150 mgPhase 31 trial
Active Trials
NCT05972044Completed516Est. Mar 2025
N
NeurocentriaCA - Walnut Creek
2 programs
1
1
NRCT-101-SRPhase 2/31 trial
NRCT-101SR, NRCT-202XRPhase 21 trial
Active Trials
NCT06673368TerminatedEst. Jul 2025
NCT05683249CompletedEst. Jan 2024
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
2 programs
CogFun RG occupational therapyN/A1 trial
tDCSN/A1 trial
Active Trials
NCT06639139Recruiting40Est. Feb 2026
NCT03104972Completed47Est. Jan 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerVery Low Dose Quillivant XR
TakedaMixed amphetamine salts
Axsome TherapeuticsSolriamfetol 150 mg
Zevra TherapeuticsKP415 oral capsule
Zevra TherapeuticsKP415 oral capsule
TevaModafinil
NovartisFocalin XR
NovartisFocalin XR
NeurocentriaNRCT-101-SR
NeurocentriaNRCT-101SR, NRCT-202XR
TakedaSPD544
Jerusalem PharmaceuticalsCogFun RG occupational therapy
Jerusalem PharmaceuticalstDCS

Clinical Trials (13)

Total enrollment: 1,499 patients across 13 trials

NCT02255565PfizerVery Low Dose Quillivant XR

Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study

Start: Sep 2014Est. completion: Oct 201636 patients
Phase 4Completed
NCT00506727TakedaMixed amphetamine salts

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Start: Aug 2003Est. completion: Jul 2004215 patients
Phase 4Completed
NCT05972044Axsome TherapeuticsSolriamfetol 150 mg

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

Start: Jul 2023Est. completion: Mar 2025516 patients
Phase 3Completed
NCT03460652Zevra TherapeuticsKP415 oral capsule

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Start: Mar 2018Est. completion: Jul 2019282 patients
Phase 3Completed
NCT03292952Zevra TherapeuticsKP415 oral capsule

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

Start: Dec 2017Est. completion: May 2018155 patients
Phase 3Completed
NCT00228540TevaModafinil

Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD

Start: Sep 2005Est. completion: Sep 2006
Phase 3Completed
NCT00141063NovartisFocalin XR

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Start: Jun 2005Est. completion: Aug 200590 patients
Phase 3Completed
NCT00141050NovartisFocalin XR

Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD

Start: May 2005Est. completion: Jul 200590 patients
Phase 3Completed
NCT05683249NeurocentriaNRCT-101-SR

Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)

Start: Feb 2023Est. completion: Jan 2024
Phase 2/3Completed
NCT06673368NeurocentriaNRCT-101SR, NRCT-202XR

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Start: Feb 2025Est. completion: Jul 2025
Phase 2Terminated
NCT01183234TakedaSPD544

SPD544 High Strength Bioequivalence Study

Start: Aug 2010Est. completion: Oct 201028 patients
Phase 1Completed
NCT06639139Jerusalem PharmaceuticalsCogFun RG occupational therapy

The Effectiveness of Cognitive-Functional Remote Group Intervention (Cog-Fun RG) for Adults with Attention Deficit Hyperactivity Disorder (ADHD)

Start: Nov 2024Est. completion: Feb 202640 patients
N/ARecruiting
NCT03104972Jerusalem PharmaceuticalstDCS

Non-invasive Brain Stimulation for Pediatric ADHD

Start: Feb 2018Est. completion: Jan 202247 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,499 patients
8 companies competing in this space